-+ 0.00%
-+ 0.00%
-+ 0.00%
InnoCare says China grants breakthrough designation for orelabrutinib-mesutoclax combo in MZL
Share
Listen to the news
InnoCare says China grants breakthrough designation for orelabrutinib-mesutoclax combo in MZL
  • China’s NMPA drug regulator granted Breakthrough Therapy Designation for orelabrutinib with mesutoclax in relapsed or refractory marginal zone lymphoma.
  • Designation covers patients who received at least one prior therapy; aims to speed development, review.
  • ASCO 2026 data showed a 100% overall response rate in the marginal zone lymphoma cohort.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608032248PRIMZONEFULLFEED9803044) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending